文献速递骨质疏松与钙磷/甲状旁腺

Jansen干骺端软骨发育不良患者矿物质离子异常的进展

Progression of Mineral Ion Abnormalities in Patients With Jansen Metaphyseal Chondrodysplasia.
PubMed 文献 · J Clin Endocrinol Metab · 2018-01-01

该研究评估了24例Jansen干骺端软骨发育不良(JMC)患者的临床和实验室表现的病程,并在体外对致病突变受体进行了功能鉴定。多数患者出生后血钙正常,但在0.15至10岁期间血钙升高(11.8 ± 1.37 mg/dL),成年后趋于正常(10.0 ± 1.03 mg/dL)。高钙尿症持续至成年。除T410R突变外,其他PTHR1突变导致相似的矿物质离子异常和严重的生长障碍。反向激动剂在体外可降低所有五种突变受体的基础cAMP信号。

要点

  • JMC患者儿童期血钙升高,成年后趋于正常,但高钙尿症持续存在。
  • 除T410R突变外,其他PTHR1突变导致相似的矿物质离子异常和生长障碍。
  • 反向激动剂可降低体外所有五种PTHR1突变体的基础cAMP信号。

核心结论

  • 除T410R外,其他PTHR1突变与不可区分的矿物质离子异常相关,并导致相似的严重生长障碍;高钙尿症持续至成年。
  • 反向激动剂配体在体外有效降低所有五种PTHR1突变体的PTH非依赖性cAMP形成,提示潜在治疗方向。

研究设计与样本

  • 评估24例JMC患者的临床和实验室表现的病程,并在体外对致病突变受体进行特征分析。
  • H223R突变见于18例患者,T410P、I458R和I458K各见于1例,T410R见于1位父亲及其2个儿子。
  • 实验室记录进行个体和汇总分析。

主要发现

  • 多数患者出生后血钙正常,但在0.15至10岁期间升高(11.8 ± 1.37 mg/dL),成年后趋于正常(10.0 ± 1.03 mg/dL)。
  • 平均磷酸盐水平处于年龄特异性正常范围的低端。
  • 尿钙/肌酐(mg/mg)持续升高(儿童0.80 ± 0.40;成人0.28 ± 0.19)。
  • 除T410R突变患者外,所有患者成年身高均远低于第3百分位。
  • 多数JMC患者接受过骨科手术,多数有肾钙质沉着症,2例患有晚期慢性肾脏病。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Five different activating PTH/PTH-related peptide (PTHrP) receptor (PTHR1) mutations have been reported as causes of Jansen metaphyseal chondrodysplasia (JMC), a rare disorder characterized by severe growth plate abnormalities and PTH-independent hypercalcemia. OBJECTIVES: Assess the natural history of clinical and laboratory findings in 24 patients with JMC and characterize the disease-causing mutant receptors in vitro. PATIENTS AND METHODS: The H223R mutation occurred in 18 patients. T410P, I458R and I458K each occurred in single cases; T410R was present in a father and his two sons. Laboratory records were analyzed individually and in aggregate. RESULTS: Postnatal calcium levels were normal in most patients, but elevated between 0.15 and 10 years (11.8 ± 1.37 mg/dL) and tended to normalize in adults (10.0 ± 1.03 mg/dL). Mean phosphate levels were at the lower end of the age-specific normal ranges. Urinary calcium/creatinine (mg/mg) were consistently elevated (children, 0.80 ± 0.40; adults, 0.28 ± 0.19). Adult heights were well below the 3rd percentile for all patients, except for those with the T410R mutation. Most patients with JMC had undergone orthopedic surgical procedures, most had nephrocalcinosis, and two had advanced chronic kidney disease. The five PTHR1 mutants showed varying degrees of constitutive and PTH-stimulated cAMP signaling activity when expressed in HEK293 reporter cells. The inverse agonist [L11,dW12,W23,Y36]PTHrP(7-36) reduced basal cAMP signaling for each PTHR1 mutant. CONCLUSIONS: Except for T410R, the other PTHR1 mutations were associated with indistinguishable mineral ion abnormalities and cause similarly severe growth impairment. Hypercalciuria persisted into adulthood. An inverse agonist ligand effectively reduced in vitro PTH-independent cAMP formation at all five PTHR1 mutants, suggesting a potential path toward therapy.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Saito H, Noda H, Gatault P, et al. Progression of Mineral Ion Abnormalities in Patients With Jansen Metaphyseal Chondrodysplasia. J Clin Endocrinol Metab. 2018. PMID: 29788189. doi:10.1210/jc.2018-00332

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。